Similarly, the CheckMate 548 study involving 716 newly diagnosed GBM patients with a methylated MGMT promoter also failed to improve the mOS (28.9 vs. 32.1 months) or median progression-free survival (mPFS, 10.6 vs. 10.3 months) upon the addition of nivolumab concurrent with the SOC [30]. The gene discussed is MGMT; the disease is glioblastoma.